Cargando…

SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments

Since the SARS-CoV-2 outbreak, pharmaceutical companies and researchers worldwide have worked hard to develop vaccines and drugs to end the SARS-CoV-2 pandemic. The potential pathogen responsible for Coronavirus Disease 2019 (COVID-19), SARS-CoV-2, belongs to a novel lineage of beta coronaviruses in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xirui, Yuan, Hao, Yang, Zipeng, Hu, Xiaoyu, Mahmmod, Yasser S., Zhu, Xiaojing, Zhao, Cuiping, Zhai, Jingbo, Zhang, Xiu-Xiang, Luo, Shengjun, Wang, Xiao-Hu, Xue, Mengzhou, Zheng, Chunfu, Yuan, Zi-Guo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780920/
https://www.ncbi.nlm.nih.gov/pubmed/36560555
http://dx.doi.org/10.3390/vaccines10122145
_version_ 1784856946865602560
author Zhang, Xirui
Yuan, Hao
Yang, Zipeng
Hu, Xiaoyu
Mahmmod, Yasser S.
Zhu, Xiaojing
Zhao, Cuiping
Zhai, Jingbo
Zhang, Xiu-Xiang
Luo, Shengjun
Wang, Xiao-Hu
Xue, Mengzhou
Zheng, Chunfu
Yuan, Zi-Guo
author_facet Zhang, Xirui
Yuan, Hao
Yang, Zipeng
Hu, Xiaoyu
Mahmmod, Yasser S.
Zhu, Xiaojing
Zhao, Cuiping
Zhai, Jingbo
Zhang, Xiu-Xiang
Luo, Shengjun
Wang, Xiao-Hu
Xue, Mengzhou
Zheng, Chunfu
Yuan, Zi-Guo
author_sort Zhang, Xirui
collection PubMed
description Since the SARS-CoV-2 outbreak, pharmaceutical companies and researchers worldwide have worked hard to develop vaccines and drugs to end the SARS-CoV-2 pandemic. The potential pathogen responsible for Coronavirus Disease 2019 (COVID-19), SARS-CoV-2, belongs to a novel lineage of beta coronaviruses in the subgenus arbovirus. Antiviral drugs, convalescent plasma, monoclonal antibodies, and vaccines are effective treatments for SARS-CoV-2 and are beneficial in preventing infection. Numerous studies have already been conducted using the genome sequence of SARS-CoV-2 in comparison with that of other SARS-like viruses, and numerous treatments/prevention measures are currently undergoing or have already undergone clinical trials. We summarize these studies in depth in the hopes of highlighting some key details that will help us to better understand the viral origin, epidemiology, and treatments of the virus.
format Online
Article
Text
id pubmed-9780920
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97809202022-12-24 SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments Zhang, Xirui Yuan, Hao Yang, Zipeng Hu, Xiaoyu Mahmmod, Yasser S. Zhu, Xiaojing Zhao, Cuiping Zhai, Jingbo Zhang, Xiu-Xiang Luo, Shengjun Wang, Xiao-Hu Xue, Mengzhou Zheng, Chunfu Yuan, Zi-Guo Vaccines (Basel) Review Since the SARS-CoV-2 outbreak, pharmaceutical companies and researchers worldwide have worked hard to develop vaccines and drugs to end the SARS-CoV-2 pandemic. The potential pathogen responsible for Coronavirus Disease 2019 (COVID-19), SARS-CoV-2, belongs to a novel lineage of beta coronaviruses in the subgenus arbovirus. Antiviral drugs, convalescent plasma, monoclonal antibodies, and vaccines are effective treatments for SARS-CoV-2 and are beneficial in preventing infection. Numerous studies have already been conducted using the genome sequence of SARS-CoV-2 in comparison with that of other SARS-like viruses, and numerous treatments/prevention measures are currently undergoing or have already undergone clinical trials. We summarize these studies in depth in the hopes of highlighting some key details that will help us to better understand the viral origin, epidemiology, and treatments of the virus. MDPI 2022-12-14 /pmc/articles/PMC9780920/ /pubmed/36560555 http://dx.doi.org/10.3390/vaccines10122145 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Zhang, Xirui
Yuan, Hao
Yang, Zipeng
Hu, Xiaoyu
Mahmmod, Yasser S.
Zhu, Xiaojing
Zhao, Cuiping
Zhai, Jingbo
Zhang, Xiu-Xiang
Luo, Shengjun
Wang, Xiao-Hu
Xue, Mengzhou
Zheng, Chunfu
Yuan, Zi-Guo
SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments
title SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments
title_full SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments
title_fullStr SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments
title_full_unstemmed SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments
title_short SARS-CoV-2: An Updated Review Highlighting Its Evolution and Treatments
title_sort sars-cov-2: an updated review highlighting its evolution and treatments
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9780920/
https://www.ncbi.nlm.nih.gov/pubmed/36560555
http://dx.doi.org/10.3390/vaccines10122145
work_keys_str_mv AT zhangxirui sarscov2anupdatedreviewhighlightingitsevolutionandtreatments
AT yuanhao sarscov2anupdatedreviewhighlightingitsevolutionandtreatments
AT yangzipeng sarscov2anupdatedreviewhighlightingitsevolutionandtreatments
AT huxiaoyu sarscov2anupdatedreviewhighlightingitsevolutionandtreatments
AT mahmmodyassers sarscov2anupdatedreviewhighlightingitsevolutionandtreatments
AT zhuxiaojing sarscov2anupdatedreviewhighlightingitsevolutionandtreatments
AT zhaocuiping sarscov2anupdatedreviewhighlightingitsevolutionandtreatments
AT zhaijingbo sarscov2anupdatedreviewhighlightingitsevolutionandtreatments
AT zhangxiuxiang sarscov2anupdatedreviewhighlightingitsevolutionandtreatments
AT luoshengjun sarscov2anupdatedreviewhighlightingitsevolutionandtreatments
AT wangxiaohu sarscov2anupdatedreviewhighlightingitsevolutionandtreatments
AT xuemengzhou sarscov2anupdatedreviewhighlightingitsevolutionandtreatments
AT zhengchunfu sarscov2anupdatedreviewhighlightingitsevolutionandtreatments
AT yuanziguo sarscov2anupdatedreviewhighlightingitsevolutionandtreatments